All In MedTech

FDA Clearance Tracker · P080012-S068

Prometra Programmable Infusion Pump System

A PMA supplement is a change to a device that already has premarket approval, such as a new indication, a design change or a manufacturing change.

Last checked: Nov 20, 2026Latest source record: Jan 12, 2022 (this decision)Source: openFDAMethods & limitations

PMA supplement

The decision

FDA number
P080012-S068
Device name
Prometra Programmable Infusion Pump System
Applicant location
Hackettstown, NJ
Received
Nov 5, 2020
Decided
Jan 12, 2022
Decision
Approved
Supplement type
Panel Track
Reason for supplement
Labeling Change - Indications/instructions/shelf life/tradename
Original approval
P080012

Device type

Device class
Class III

Every decision under product code LKK

FDA's approval statement

As written in FDA's record.

Approval for the Prometra® Programmable Infusion Pump System. The device is indicated for intrathecal infusion of drug therapy, including: Infumorph ® (preservative free morphine sulfate sterile solution), preservative-free sterile 0.9% saline solution (Sodium Chloride Injection, USP), and baclofen (baclofen injection, intrathecal, 500-2000 mcg/mL). For Infumorph, the pump system is indicated for use in patient populations of 22 years and older (adults). For baclofen, the pump system is indicated for use in patient populations of 12 years and older (pediatric adolescents and adults).

Source documents

Other decisions for Infusyn Therapeutics, LLC

Matched on the applicant name as FDA recorded it. A company that files under several names will have more.

Company page

No other decisions since 2015 under this exact applicant name.

For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.